Similarly, mTORC1 activation predicts responsiveness to RAF or MEK inhibitors in BRAF-mutant melanoma; in tumors that do not respond, pRPS6 remains activated and combining mTORC1 inhibition with RAF or MEK inhibition induces a cytotoxic response [25]. This evidence concerns the gene MAP2K7 and melanoma.